

Cytoplasmic dynein 1 (dynein) is the predominant microtubule minus end-directed motor in animals and participates in a wide range of cellular processes, including membrane trafficking, nuclear migration, and cell division. Dynein's functional diversity depends on co-factors that regulate its subcellular localization, interaction with cargo, and motor activity. The ubiquitous co-factor nuclear distribution gene E (NudE) is implicated in many of dynein's functions, and mutations in NudE cause the brain developmental disease microcephaly. To identify genetic interactors of the Caenorhabditis elegans NudE homolog nud-2, we performed a genome-wide RNAi screen with the null allele nud-2(ok949), which compromises dynein function but leaves animals viable and fertile. Using bacterial feeding to deliver dsRNAs in a 96-well liquid format and a semi-automated fluorescence microscopy approach for counting parents and progeny, we screened 19762 bacterial clones and identified 38 genes whose inhibition caused enhanced lethality in nud-2(ok949) relative to the nud-2(+) control. Further study of these genes, many of which participate in cell division, promises to provide insight into the function and regulation of dynein. © The Author(s) 2018.
| EMTREE drug terms: | Caenorhabditis elegans proteincarrier proteincytoplasmic dynein |
|---|---|
| EMTREE medical terms: | animalCaenorhabditis elegansgeneticsgenomeRNA interference |
| MeSH: | AnimalsCaenorhabditis elegansCaenorhabditis elegans ProteinsCarrier ProteinsCytoplasmic DyneinsGenome, HelminthRNA Interference |
carrier protein, 80700-39-6;
Caenorhabditis elegans Proteins; Carrier Proteins; Cytoplasmic Dyneins
| Funding sponsor | Funding number | Acronym |
|---|---|---|
| European Molecular Biology Organization See opportunities | ||
| Seventh Framework Programme | ||
| European Research Council | ||
| Norte-01-0145-FEDER-000029-Advancing,SFRH/BD/103495/2014,IF/01015/2013/CP1157/CT0006 | ||
| European Research Council | ||
| 2545 | ||
| European Regional Development Fund | ||
| NORTE 2020 |
The authors acknowledge the support of the BioSciences Screening i3S Scientific Platform. Funding for this project was provided by the European Research Council under the European Union's Seventh Framework Programme (ERC grant agreement n o ERC-2013-StG-338410-DYNEINOME to R.G.), by the European Molecular Biology Organization (EMBO Installation Grant 2545 to R.G.), by the Fundacao para a Ciencia e a Tecnologia (IF/01015/2013/CP1157/CT0006 to R.G. and SFRH/BD/103495/2014 to H. R.), and by 'Norte-01-0145-FEDER-000029-Advancing cancer research: from basic knowledge to application', supported by the Norte Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement through the European Regional Development Fund (FEDER)
Maia, A.F.; Instituto de Investigação e Inovação em Saúde (i3S), Universidade Do Porto, Porto, Portugal;
© Copyright 2018 Elsevier B.V., All rights reserved.